← Leaderboards
Laurence S Jacobs
University Of Rochester
$83,599
Attributed
$83,599
Total exposure
3
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding mix
By agency
NIH$83,599 · 3
By mechanism
M01$83,599 · 3
Top collaborators
No co-investigators on record.
Most similar at University Of Rochester
Same institution · by research overlap
- Berislav V Zlokovic$52,237,055
- Mahin D. Maines$9,697,031
- Thomas Harrison Foster$6,987,839
- Krystel R Huxlin$15,462,188
- Thomas R Gaborski$4,640,521
Others in their field
Top investigators on “Diabetes Mellitus Therapy”
- David M Nathan · Massachusetts Institute Of Technology$140,313,171
- John M Lachin · George Washington University$134,552,372
- Kathryn Hirst · Caritas St. Elizabeth'S Medical Center$126,225,488
- Judith S Hochman · New York University School Of Medicine$100,149,457
- Rose A Gubitosi-Klug · Case Western Reserve University$64,112,836
- David Heimbrook · Leidos Biomedical Research, Inc.$56,712,245
Research focus
Diabetes Mellitus TherapyNoninsulin Dependent Diabetes MellitusClinical ResearchHuman SubjectTroglitazoneHuman Therapy EvaluationAntihypercholesterolemic AgentDrug Screening /EvaluationTriglyceridesBlood Disorder ChemotherapyHemoglobin AsHmg Coa ReductasesCombination ChemotherapyBlood LipoproteinEnzyme ActivityHyperlipidemiaBlood GlucoseOxidoreductase InhibitorPharmacokineticsDosageHypercholesterolemia
Grant awards (5)
6-MONTH STUDY OF TROGLITAZONE (CI-991) IN PATIENTS WITH NIDDM$19,613
M01 · FY2001 · RR
ATORVASTATIN (CI-981) ADDED TO TROGLITAZONE IN TYPE II DIABETES MELLITUS$19,613
M01 · FY2001 · RR
6-MONTH STUDY OF TROGLITAZONE (CI-991) IN PATIENTS WITH NIDDM$14,791
M01 · FY2000 · RR
COMPARE E&T OF SIMVASTATIN &ATORVASTATIN IN TYPE 2 DM$14,791
M01 · FY2000 · RR
ATORVASTATIN (CI-981) ADDED TO TROGLITAZONE IN TYPE II DIABETES MELLITUS$14,791
M01 · FY2000 · RR